A major advancement in the development of apoE-based gene therapies was recently reported with the AAV-mediated expression of an apoE variant combining the apoE2 and Christchurch variant in amyloid and tau-based AD mouse models. The gene discussed is MAPT; the disease is Alzheimer disease.